NASDAQ:BEAM - Beam Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $110.86
  • Forecasted Upside: 138.45 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$46.49
▲ +6.7 (16.84%)

This chart shows the closing price for BEAM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beam Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAM

Analyst Price Target is $110.86
▲ +138.45% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $110.86, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 138.45% upside from the last price of $46.49.

This chart shows the closing price for BEAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Beam Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/12/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/9/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/7/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/7/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/6/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/6/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/16/2022BMO Capital MarketsInitiated CoverageMarket Perform$41.00High
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$62.00High
2/28/2022WedbushLower Price TargetOutperform$159.00 ➝ $152.00High
1/10/2022WedbushBoost Price Target$148.00 ➝ $159.00High
1/10/2022SVB LeerinkBoost Price TargetOutperform$116.00 ➝ $121.00High
1/5/2022GuggenheimInitiated CoverageBuy$130.00High
11/9/2021SVB LeerinkLower Price TargetOutperform$117.00 ➝ $116.00Medium
10/19/2021SVB LeerinkInitiated CoverageOutperform$117.00High
9/24/2021Stifel NicolausInitiated CoverageBuy$85.00 ➝ $120.00Medium
9/10/2021Bank of AmericaInitiated CoverageBuy$150.00Low
6/29/2021WedbushBoost Price TargetOutperform$114.00 ➝ $149.00Medium
5/11/2021Redburn PartnersInitiated CoverageBuyHigh
5/3/2021Royal Bank of CanadaInitiated CoverageSector Perform$85.00High
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$47.00 ➝ $90.00Low
2/25/2021WedbushBoost Price Target$42.00 ➝ $112.00High
2/16/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00Low
1/5/2021Stifel NicolausInitiated CoverageHoldN/A
10/16/2020WedbushReiterated RatingOutperform$40.00N/A
8/12/2020William BlairInitiated CoverageBuyN/A
8/5/2020William BlairReiterated RatingOutperform$33.00Medium
8/5/2020William BlairInitiated CoverageOutperform$33.00N/A
5/13/2020WedbushReiterated RatingOutperform$32.00N/A
3/2/2020WedbushReiterated RatingOutperformHigh
3/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$31.00N/A
3/2/2020WedbushInitiated CoverageOutperform ➝ Outperform$32.00 ➝ $32.00N/A
3/2/2020Jefferies Financial GroupInitiated CoverageBuy$32.00N/A
3/2/2020BarclaysInitiated CoverageOverweight$32.00N/A
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/8/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/7/2022
  • 4 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
2/6/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/8/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/7/2022
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/7/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
6/6/2022
  • 1 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
7/6/2022

Current Sentiment

  • 1 very positive mentions
  • 15 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $46.49
Low: $38.96
High: $46.57

50 Day Range

MA: $36.51
Low: $29.86
High: $46.49

52 Week Range

Now: $46.49
Low: $27.77
High: $129.50

Volume

1,794,427 shs

Average Volume

1,196,525 shs

Market Capitalization

$3.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Beam Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Beam Therapeutics in the last year: Bank of America Co., BMO Capital Markets, Credit Suisse Group AG, Guggenheim, Stifel Nicolaus, SVB Leerink LLC, and Wedbush.
View the latest analyst ratings for BEAM.

What is the current price target for Beam Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Beam Therapeutics in the last year. Their average twelve-month price target is $110.86, suggesting a possible upside of 138.5%.
View the latest price targets for BEAM.

What is the current consensus analyst rating for Beam Therapeutics?

Beam Therapeutics currently has 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BEAM will outperform the market and that investors should add to their positions of Beam Therapeutics.
View the latest ratings for BEAM.

How do I contact Beam Therapeutics' investor relations team?

Beam Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-327-8775 and its investor relations email address is [email protected] The official website for Beam Therapeutics is www.beamtx.com. Learn More about contacing Beam Therapeutics investor relations.